Chemotherapy Options For Hodgkin’s Lymphoma Guided By PET Scans

PET scans administered midway through treatment can help doctors decide which chemotherapy choices will work best for patients with Hodgkin’s lymphoma.

According to a study published in the Journal of Clinical Oncology, determining the correct regimen midway through chemotherapy can help doctors successfully treat patients with advanced Hodgkins lymphoma and minimize the ill effects of these types of drugs. Chemotherapy treatments have a 70 percent success rate in the United States.

“The outcome of this large study was very encouraging and suggested that this approach could maximize cure rates for advanced Hodgkin’s lymphoma while minimizing toxicities for the majority of patients,” said Dr. Oliver Press, a lymphoma physician and lead author of the study.

PET scan predictions

Researchers claim that the amount of cancer cells detected during a PET scan at the midway point of chemotherapy can help doctors determine the best course of action for individual patients during the remainder of their treatments.

During the study patients were scanned to look for remaining destructive tumor cells in the lymph nodes. If a PET scan revealed lingering cancer cells, those patients received a more aggressive regimen of chemotherapy. If less threatening tumor cells were revealed during the scan, patients’ treatments would be scaled back to minimize chemotherapy's side effects.

“Hodgkin’s lymphoma is one of the examples of a disease that [response-adapted therapy] makes the most sense in,” said Dr. Jonathan Friedberg, second author of the study. “Because we’re already curing a lot of patients with Hodgkin’s lymphoma, it suggests that there’s a subset of patients [in whom] we’d like to de-escalate treatment to limit toxicity, and also for that smaller fraction of people whom we’re not curing, to escalate treatment.”

Source: Lymphoma News Today

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap